MX2007005256A - Vacunas multivalentes que comprenden vectores virales recombinantes. - Google Patents
Vacunas multivalentes que comprenden vectores virales recombinantes.Info
- Publication number
- MX2007005256A MX2007005256A MX2007005256A MX2007005256A MX2007005256A MX 2007005256 A MX2007005256 A MX 2007005256A MX 2007005256 A MX2007005256 A MX 2007005256A MX 2007005256 A MX2007005256 A MX 2007005256A MX 2007005256 A MX2007005256 A MX 2007005256A
- Authority
- MX
- Mexico
- Prior art keywords
- antigens
- relates
- recombinant vectors
- vectors
- viral vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
La invencion se refiere a vacunas que comprenden vectores recombinantes, tales como adenovirus recombinantes. Los vectores comprenden acidos nucleicos heterologos que codifican para al menos dos antigenos de uno o mas bacilos que causan tuberculosis. La invencion tambien se refiere al uso de antigenos que ligan sitios de reconocimiento de proteasa especificos a traves de los cuales los antigenos codificados se separan durante el desdoblamiento. Despues del desdoblamiento, los antigenos contribuyen a la respuesta inmune en una manera separada. Los vectores recombinantes pueden comprender un acido nucleico que codifica la proteasa desdoblando los ligadores y separando los antigenos. La invencion adicionalmente se refiere al uso de adyuvantes geneticos codificados por vectores recombinantes, en donde tales adyuvantes geneticos puede tambien desdoblarse a traves de la presencia de ligadores de desdoblamiento y la proteasa especifica.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62825304P | 2004-11-16 | 2004-11-16 | |
EP04106074 | 2004-11-25 | ||
US65111305P | 2005-02-08 | 2005-02-08 | |
PCT/EP2005/055984 WO2006053871A2 (en) | 2004-11-16 | 2005-11-15 | Multivalent vaccines comprising recombinant viral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007005256A true MX2007005256A (es) | 2008-03-11 |
Family
ID=34929936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005256A MX2007005256A (es) | 2004-11-16 | 2005-11-15 | Vacunas multivalentes que comprenden vectores virales recombinantes. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8012467B2 (es) |
EP (1) | EP1812580B1 (es) |
JP (1) | JP4838259B2 (es) |
KR (1) | KR101255870B1 (es) |
CN (2) | CN102220357B (es) |
AU (2) | AU2005305869B2 (es) |
BR (1) | BRPI0518933A2 (es) |
CA (1) | CA2586620C (es) |
EA (1) | EA012037B1 (es) |
MX (1) | MX2007005256A (es) |
NZ (2) | NZ581306A (es) |
SG (2) | SG159554A1 (es) |
WO (1) | WO2006053871A2 (es) |
ZA (1) | ZA200703838B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
WO2006053871A2 (en) | 2004-11-16 | 2006-05-26 | Crucell Holland B.V. | Multivalent vaccines comprising recombinant viral vectors |
US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
BRPI0806501A2 (pt) * | 2007-01-15 | 2014-04-22 | Glaxosmithkline Biolog Sa | Proteína de fusão, molécula de ácido nucleico, vetor, célula hospedeira, vacina ou composição imunogênica, e, uso da proteína de fusão. |
GB0719509D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Molecular adjuvant |
EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
US20100015171A1 (en) | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
AP2011005541A0 (en) * | 2008-07-16 | 2011-02-28 | Baylor Res Inst | HIV vaccine based on targeting maximized GAG and NEF to dendritic cells. |
MX2011004292A (es) | 2008-11-03 | 2011-05-31 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales. |
EP2358757B1 (en) | 2008-11-18 | 2018-09-12 | Beth Israel Deaconess Medical Center | Antiviral vaccines with improved cellular immunogenicity |
TR201903223T4 (tr) * | 2009-04-24 | 2019-03-21 | Statens Seruminstitut | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. |
CA2786835C (en) | 2010-02-15 | 2021-08-31 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
GB201008512D0 (en) | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
EP2618838A1 (en) * | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
CN102154324B (zh) * | 2010-12-29 | 2012-11-28 | 兰州大学 | 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用 |
CN102260712B (zh) * | 2011-05-31 | 2013-10-02 | 北京锤特生物科技有限公司 | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 |
AU2012343981B2 (en) | 2011-11-28 | 2017-09-07 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
HUE027839T2 (en) | 2012-03-12 | 2016-11-28 | Crucell Holland Bv | Recombinant adenoviruses with altered terminals |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
JP2015515276A (ja) | 2012-04-16 | 2015-05-28 | アエラス グローバル ティービー ワクチン ファウンデーション | ヘパリン結合性赤血球凝集素(hbha)融合タンパク質とその用途をコードする組換え型マイコバクテリウム |
WO2014009438A2 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
CN103304670B (zh) * | 2013-06-03 | 2015-09-16 | 中国人民解放军第三〇九医院 | 结核分枝杆菌特异性融合蛋白疫苗ab及其制备和应用 |
AP2016009154A0 (en) | 2013-09-19 | 2016-04-30 | Crucell Holland Bv | Improved adenovirus formulations |
CN103865934B (zh) * | 2014-03-26 | 2017-02-22 | 中国人民解放军成都军区疾病预防控制中心 | 银环毒素抗原表位基因及其在基因疫苗及抗原制备中的应用 |
NZ727024A (en) | 2014-06-26 | 2022-02-25 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
CA2981841A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
JP6873054B2 (ja) * | 2015-06-12 | 2021-05-19 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
EA036412B1 (ru) | 2015-10-06 | 2020-11-09 | Янссен Вэксинс Энд Превеншн Б.В. | Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса |
US11473105B2 (en) | 2016-05-12 | 2022-10-18 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2017220499A1 (en) | 2016-06-20 | 2017-12-28 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018075559A1 (en) | 2016-10-17 | 2018-04-26 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
CN106754758A (zh) * | 2016-12-29 | 2017-05-31 | 汕头大学医学院 | 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用 |
CN110268061A (zh) | 2017-02-09 | 2019-09-20 | 扬森疫苗与预防公司 | 用于表达异源基因的有效的短启动子 |
CN107602672B (zh) * | 2017-08-30 | 2021-06-18 | 广州医科大学附属第一医院 | 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法 |
CN107365365B (zh) * | 2017-08-30 | 2021-01-01 | 广州医科大学附属第一医院 | 重组表达的腺病毒纤毛蛋白肽、腺病毒亚单位疫苗及其制备方法 |
EP3700561A1 (en) | 2017-10-27 | 2020-09-02 | Statens Serum Institut | A polygene influenza vaccine |
EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2042016C (en) | 1989-09-19 | 2004-04-06 | Jean Content | Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis |
EP0499003A1 (en) | 1991-02-14 | 1992-08-19 | N.V. Innogenetics S.A. | Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis |
US6641814B1 (en) | 1997-04-02 | 2003-11-04 | Statens Serum Institut | Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis |
US5955077A (en) | 1993-07-02 | 1999-09-21 | Statens Seruminstitut | Tuberculosis vaccine |
DK79893D0 (da) | 1993-07-02 | 1993-07-02 | Statens Seruminstitut | New vaccine |
AU1097795A (en) | 1993-11-23 | 1995-06-13 | Regents Of The University Of California, The | Abundant extracellular products and methods for their production and use |
US6599510B1 (en) | 1993-11-23 | 2003-07-29 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
JPH11506320A (ja) | 1995-05-23 | 1999-06-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 豊富な細胞外産物、ならびにそれらを産生および使用するための方法 |
EP0850305B1 (en) | 1995-09-01 | 2006-04-26 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
TR200806259T2 (tr) | 1995-09-01 | 2008-10-21 | Corixa Corporation | Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler |
US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6338852B1 (en) | 1995-09-01 | 2002-01-15 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US6087163A (en) | 1997-02-06 | 2000-07-11 | The Public Health Research Institute Of The City Of New York, Inc. | Mycobacterium tuberculosis specific proteins and genes, mixtures of anitgens and uses thereof |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
TR199901569T2 (xx) | 1996-10-11 | 2000-12-21 | Corixa Corporation | T�berk�lozun te�hisi i�in bile�ikler ve y�ntemler. |
JP2001512435A (ja) | 1997-01-21 | 2001-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 豊富な細胞外産物ならびにそれらの産生および使用方法 |
US6544522B1 (en) | 1998-12-30 | 2003-04-08 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
US6627198B2 (en) | 1997-03-13 | 2003-09-30 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis antigens and their uses |
US6350456B1 (en) | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
ES2291810T3 (es) | 1997-04-02 | 2008-03-01 | Statens Serum Institut | Fragmentos de acido nucleico y fragmentos de polpeptidos derivados de m. tuberculosis. |
US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US6555653B2 (en) | 1997-05-20 | 2003-04-29 | Corixa Corporation | Compounds for diagnosis of tuberculosis and methods for their use |
US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
US6436409B1 (en) | 1997-07-16 | 2002-08-20 | Institut Pasteur | Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same |
WO2001004151A2 (en) | 1999-07-13 | 2001-01-18 | Statens Serum Institut | TUBERCULOSIS VACCINE AND DIAGNOSTICS BASED ON THE MYCOBACTERIUM TUBERCULOSIS esat-6 GENE FAMILY |
EP1029053A1 (en) | 1997-11-10 | 2000-08-23 | Statens Seruminstitut | Nucleic acid fragments and polypeptide fragments derived from mycobacterium tuberculosis |
TWI243169B (en) | 1998-03-02 | 2005-11-11 | Nissan Chemical Ind Ltd | Optically active epoxy compound |
TR200002938T2 (tr) | 1998-04-07 | 2001-02-21 | Corixa Corporation | Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı |
US20020150592A1 (en) | 1998-09-18 | 2002-10-17 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
AU766093B2 (en) | 1998-10-08 | 2003-10-09 | Statens Serum Institut | Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell |
US6465633B1 (en) | 1998-12-24 | 2002-10-15 | Corixa Corporation | Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis |
AU2594500A (en) | 1998-12-24 | 2000-07-31 | Corixa Corporation | Methods for using mycobacterium tuberculosis molecules as immunological adjuvants |
US20030027774A1 (en) | 1999-03-18 | 2003-02-06 | Ronald C. Hendrickson | Tuberculosis antigens and methods of use therefor |
PT1818408E (pt) | 1999-05-17 | 2011-11-15 | Crucell Holland Bv | Adenovírus recombinante do serótipo ad11 |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
WO2001023421A2 (en) | 1999-09-30 | 2001-04-05 | Corixa Corporation | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
US20020039583A1 (en) | 1999-09-30 | 2002-04-04 | Subjeck John R. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
WO2001025401A2 (en) | 1999-10-07 | 2001-04-12 | Corixa Corporation | A mycobacterium tuberculosis coding sequence for expression of heterologous proteins |
JP2003510370A (ja) | 1999-10-07 | 2003-03-18 | コリクサ コーポレイション | Mycobacteriumtuberculosisの融合タンパク質 |
AU2001241738A1 (en) | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
GB0006693D0 (en) | 2000-03-20 | 2000-05-10 | Glaxo Group Ltd | Vaccine |
AU2001250294A1 (en) | 2000-04-19 | 2001-10-30 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
US7754201B2 (en) | 2000-06-02 | 2010-07-13 | GenPhar, Inc | Method of vaccination through serotype rotation |
ES2374620T3 (es) | 2000-06-20 | 2012-02-20 | Corixa Corporation | Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos. |
AU2002318104A1 (en) * | 2001-01-05 | 2002-11-25 | Corixa Corporation | Microparticles and methods for delivery of recombinant viral vaccines |
ES2375557T3 (es) | 2001-06-22 | 2012-03-02 | The Trustees Of The University Of Pennsylvania | Adenovirus recombinantes que comprenden prote�?nas de adenovirus de simios y usos de los mismos. |
AU2002365366B2 (en) | 2001-11-21 | 2007-05-10 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
WO2003070187A2 (en) * | 2002-02-15 | 2003-08-28 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
ATE447037T1 (de) | 2002-04-25 | 2009-11-15 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
NZ534865A (en) | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
AU2003288273A1 (en) * | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
EP1606397A1 (en) | 2003-03-17 | 2005-12-21 | Merck & Co., Inc. | Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
KR100992646B1 (ko) * | 2003-07-09 | 2010-11-05 | 제이에스알 가부시끼가이샤 | 파장판 |
JP2007515386A (ja) * | 2003-09-18 | 2007-06-14 | メルク エンド カムパニー インコーポレーテッド | Hiv感染個体の治療用免疫化 |
WO2005061534A2 (en) * | 2003-12-23 | 2005-07-07 | Statens Serum Institut | Improved tuberculosis vaccines |
WO2006053871A2 (en) | 2004-11-16 | 2006-05-26 | Crucell Holland B.V. | Multivalent vaccines comprising recombinant viral vectors |
DK1827504T3 (da) * | 2004-12-01 | 2011-08-29 | Aeras Global Tb Vaccine Foundation | Rekombinante BCG-stammer med forøget evne til at undslippe fra endosomet |
CA2615983A1 (en) * | 2005-07-21 | 2007-02-01 | Abbott Laboratories | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
-
2005
- 2005-11-15 WO PCT/EP2005/055984 patent/WO2006053871A2/en active Application Filing
- 2005-11-15 SG SG201001023-9A patent/SG159554A1/en unknown
- 2005-11-15 MX MX2007005256A patent/MX2007005256A/es active IP Right Grant
- 2005-11-15 CA CA2586620A patent/CA2586620C/en not_active Expired - Fee Related
- 2005-11-15 CN CN2011100927875A patent/CN102220357B/zh not_active Expired - Fee Related
- 2005-11-15 EP EP05808008.6A patent/EP1812580B1/en active Active
- 2005-11-15 CN CN2005800390957A patent/CN101090974B/zh not_active Expired - Fee Related
- 2005-11-15 NZ NZ581306A patent/NZ581306A/en not_active IP Right Cessation
- 2005-11-15 EA EA200701084A patent/EA012037B1/ru unknown
- 2005-11-15 NZ NZ555907A patent/NZ555907A/en not_active IP Right Cessation
- 2005-11-15 BR BRPI0518933-0A patent/BRPI0518933A2/pt not_active Application Discontinuation
- 2005-11-15 JP JP2007540658A patent/JP4838259B2/ja not_active Expired - Fee Related
- 2005-11-15 SG SG201001024-7A patent/SG159555A1/en unknown
- 2005-11-15 KR KR1020077013631A patent/KR101255870B1/ko active IP Right Grant
- 2005-11-15 AU AU2005305869A patent/AU2005305869B2/en not_active Ceased
- 2005-11-15 US US11/667,975 patent/US8012467B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 ZA ZA2007/03838A patent/ZA200703838B/en unknown
-
2011
- 2011-02-22 AU AU2011200749A patent/AU2011200749B9/en not_active Ceased
- 2011-05-31 US US13/134,190 patent/US8202723B2/en active Active
- 2011-05-31 US US13/134,206 patent/US8609402B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG159555A1 (en) | Multivalent vaccines comprising recombinant viral vectors | |
NO20072470L (no) | Malariaigangsetter/forsterkervaksine | |
WO2007106476A3 (en) | Compositions and methods for enhancing the immunogenicity of antigens | |
WO2006127956A3 (en) | Rapid production of adenovirus-free recombinant adenovirus vectors | |
JP2014195454A5 (es) | ||
WO2005012537A3 (en) | Adenoviral vector-based vaccines | |
WO2006073431A3 (en) | Avipox recombinants expressing foot and mouth disease virus genes | |
WO2007062656A3 (en) | A nucleotide vaccine | |
WO2008115199A3 (en) | Chimeric virus vaccines | |
MY150105A (en) | A novel surface exposed haemophilus influenzae protein (protein e; pe) | |
HK1091217A1 (en) | Tuberculosis vaccine with improved efficacy | |
TW200621287A (en) | Vaccines | |
WO2009117116A3 (en) | Heat shock protein gp96 vaccination and methods of using same | |
IN2009CN03372A (es) | ||
WO2003066820A3 (en) | Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof | |
WO2006064378A3 (en) | Adjuvant activity of gastrointestinal peptides | |
PT1962889E (pt) | Polipéptido imunogénico formado por péptidos crípticos optimizados provenientes de antigénios tumorais, e suas utilizações | |
WO2001074845A3 (en) | Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof | |
MX2010010025A (es) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. | |
WO2003089571A3 (en) | Ehrlichia canis genes and vaccines | |
WO2006113782A3 (en) | Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof | |
EP1090995A3 (en) | Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof | |
WO2005089101A3 (en) | Non-pathogenic listeria vaccine vectors and methods of treatment therewith | |
TW200604207A (en) | A superantigen fusion protein and the use thereof | |
WO2004087886A3 (en) | Modified adenoviral e1a constructs and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |